GX Acquisition Corporation (GXGX) Quote

Every time this starts to run...they dump shares.

Celularity Inc has closed the merger with GX Acquisition Corp (NASDAQ: GXGX), giving Celularity $138 million to push the NK cell and T cell therapies into early-stage trials.
The combined company will operate under the name Celularity Inc (NASDAQ: CELU), and its common stock will commence trading on the NASDAQ from Monday (19 July) under the ticker symbol CELU.
The company expanded its ongoing Phase 1 trial of CYNK-001 in patients with acute myeloid leukemia (AML)to include patients with relapsed/refractory AML (r/r AML) in addition to its ongoing trial in measurable residual disease (MRD).
To date, no dose-limiting toxicity was observed with outpatient administration of three doses.
The FDA granted Orphan Drug Designation to CYNK-001 for the treatment of patients with malignant gliomas.
CYNK-001 is currently in a Phase 1 trial for glioblastoma multiforme.
For Phase 1/2 COVID-19 trial assessing CYNK-001, no evidence of dose-limiting toxicities or evidence of no worsening inflammatory biomarkers was observed, and enrollment is ongoing.

GXGX will be trading on the Nasdaq Capital Market on July 19, 2021, under the ticker symbol "CELU." Celularity's management team will continue leading the merged company following this transaction.

https://celularity.com/celularity-and-gx-acquisition-corp-announce-merger-agreement-to-create-a-publicly-listed-leader-in-allogeneic-cellular-therapy/

Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy – Celularity

Just bought 1,000 shares today. This company looks great. It should have a steady increase short term.

If you are deciding to buy this mid to high risk stock, GXGX, here is what they are.

Click on link below and listen to broadcast.

Joint Investor Conference Call – Celularity
https://celularity.com/joint-investor-conference-call/